Dr Kuno van der Post
OmniComm Systems, Inc.
FORT LAUDERDALE, Fla., June 12, 2013 -- OmniComm Systems, Inc. (OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, and Reliable Lifesciences Consulting (RELICO), a leading eClinical consulting services firm, announced their new strategic partnership today. The partnership will allow OmniComm to offer best-in-class EDC project management and support, and add to OmniComm's own European based support services, while allowing RELICO to offer study build and support services to its clients as well as access to one of the most intuitive, productive EDC suites available on the market today.
"OmniComm is delighted to partner with RELICO," said Stephen Johnson, President & COO, OmniComm Systems. "RELICO's vast experience and good standing in the life science community, extends the reach for OmniComm particularly within Europe and the Middle East. They have a distinctive reputation for efficiency and scalability, managing projects for large pharma and small biotech alike and more importantly, getting it right the first time."
OmniComm's System Integrator Partner Program is focused on building out a global support ecosystem of proven companies dedicated to the eClinical market place. Both of OmniComm's key products, TrialMasterTM and TrialOneTM, offer an intuitive user experience and lower total cost of ownership. Clients will gain enhanced benefits from RELICO's expertise across different platforms, especially in terms of multivendor eClinical systems integration with diverse functional requirements and capabilities.
"By becoming an OmniComm partner, RELICO is aligning itself with the fastest growing EDC providers in the industry," said Dr Hauke Kindler, RELICO's CEO & Founder. "Their proven reliability and very strong focus on interoperability and innovation is seeing them out-perform the older, aging EDC systems that are currently available."
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
RELICO (www.relico.de) is a provider of expert consulting services and software as a service for the life sciences industry with offices in Germany and Switzerland. Providing the highest quality of eClinical capabilities to RELICO's pharmaceutical, medical device and CRO customers for the last 10 years, RELICO is committed to delivering efficient end-to-end solutions that allow RELICO's clients to focus more successfully on their core business requirements.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.